Graft trussing and suspension construct
US-2024358496-A1 · Oct 31, 2024 · US
US9889235B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9889235-B2 |
| Application number | US-201414765662-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 5, 2014 |
| Priority date | Feb 5, 2013 |
| Publication date | Feb 13, 2018 |
| Grant date | Feb 13, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
In one aspect, the invention provides an implantable device comprising a uniform mixture of components including degradable polymer, inorganic bone particulate either natural or synthetic, a drug, and a soluble microporagen. In some embodiments, the uniform mixture further includes a soluble polymer macroporagen. In some embodiments, the uniform mixture is coated with an immobilized outer porous layer comprising or consisting of synthetic or natural inorganic bone granules. In further aspects, the invention provides an implantable device comprising a composite core of degradable polymer, bone, and a drug, and a coating comprising or consisting of microporous bone overlayer covering the degradable composite core.
Opening claim text (preview).
What is claimed is: 1. An implantable device comprising a uniform mixture of components including: degradable polymer comprising a composition selected from the group consisting of polycaprolactone, poly(lactic-co-glycolic) acid, and mixtures thereof, bone, a drug, a macroporagen including polyethylene glycol, and a microporagen selected from the group consisting of CaCl 2 , MgCl 2 , and MgCO 3 , wherein: (a) the amount of bone by weight exceeds the combined weight of all the other components, (b) the components are selected and provided in relative amounts such that following implantation; (i) water molecules dissolve the microporagen to create micropores in the device, (ii) the water molecules enter the resulting micropores, (iii) the entering water molecules dissolve or degrade the macroporagen and the degradable polymer, (iv) the drug is released while creating sufficient space for cell migration into the device and while retaining structural integrity of the device long enough to serve as a scaffold to establish osteoconduction, and (c) the degradable polymer has a degree of crystallinity and molecular weight which render the device resorbable and able to release the drug over a time period of at least six weeks following implantation. 2. The device of claim 1 , wherein the bone is synthetic bone. 3. The device of claim 1 , wherein the macroporagen further includes a composition selected from the group consisting of alginate, polyvinylpyrrolidone, NaCMC, hydroxypropylcelluose, hyaluronic acid, and combinations of the foregoing. 4. The device of claim 1 , further comprising a coating covering the uniform mixture. 5. The device of claim 4 , wherein the coating comprises bone. 6. The device of claim 1 , wherein the drug is microencapsulated. 7. The device of claim 1 , wherein the amount of degradable polymer by weight exceeds the amount of macroporagen by weight, and the amount of macroporagen by weight exceeds the amount of microporagen by weight. 8. A method for treating and/or preventing infection at a site of implantation in a patient in need of a bone or joint replacement, comprising implanting the device of claim 1 into the site of implantation. 9. A method for manufacturing the device of claim 1 comprising: a) combining the degradable polymer comprising a composition selected from the group consisting of polycaprolactone poly(lactic-co-glycolic) acid and mixtures thereof, the drug, the bone, the macroporagen including polyethylene glycol, and the microporagen selected from the group consisting of CaCl 2 , MgCl 2 , and MgCO 3 over heat to make a uniform mixture by increasing the mixture temperature; b) dispensing the heated uniform mixture into a mold of a pre-determined shape and size according to an anatomical need; c) cooling the uniform mixture to a temperature at which the uniform mixture will harden in the mold; and d) releasing the hardened uniform mixture from the mold to produce the device. 10. The method of claim 9 , wherein the method further comprises e) contacting the surface of the implantable device produced by step (d) with morselized bone, and f) allowing the morselized bone to embed into the surface of the device to form a coating of bone on the device using mechanical force, ultrasonic energy or locally applied heat. 11. The method of claim 9 , wherein the uniform mixture is a composite.
Tissue-regenerating or healing or proliferative agents · CPC title
Materials at least partially resorbable by the body · CPC title
for joint reconstruction · CPC title
Bone, e.g. demineralised bone matrix [DBM], bone powder · CPC title
characterised by the choice of material · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.